Wis. man dies of asthma when cops stop car on way to ER – New York Daily News


New York Daily News

Wis. man dies of asthma when cops stop car on way to ER
New York Daily News
A Wisconsin man died of a severe asthma attack after the speeding car rushing him to a hospital was pulled over for running a red light, police said. Now, the man's girlfriend, Leah Hryniewicki, says the Chippewa Falls, Wis., police department is
Man having asthma attack dies after officer stops speeding car, calls for helpMinneapolis Star Tribune
WI man dies of asthma attack while pulled overKARE
Man dies of asthma when cop stops him for running a red light and won't let Raw Story
Daily Mail –Madison.com
all 43 news articles »

View full post on asthma – Google News

Asthmatic? Stop worrying about smells – TheHealthSite


TheHealthSite

Asthmatic? Stop worrying about smells
TheHealthSite
asthma Are you an asthmatic and constantly worried about scents and fragrances in the surrounding air? This thought alone can actually harm you more than you can think of. A new research reveals that simply believing that an odour is potentially
Asthmatic? Why you must stop worrying about smellsHindustan Times

all 12 news articles »

View full post on asthma – Google News

KaloBios to Stop KB003 Development for Asthma – Analyst Blog – NASDAQ

KaloBios to Stop KB003 Development for Asthma – Analyst Blog
NASDAQ
KaloBios Pharmaceuticals, Inc. ( KBIO ) announced disappointing top line results from a phase II study on KB003 in patients suffering from severe asthma, where the candidate failed to meet the key endpoints. We expect the news to have a significant
KaloBios shares tank on failed asthma drug trialSan Francisco Business Times (blog)
KaloBios calls it quits on its asthma drug after a Phase II flopFierceBiotech
KaloBios Pharma pulls plug on asthma drug, shares plungeReuters
MarketWatch
all 32 news articles »

View full post on asthma – Google News

KaloBios to Stop KB003 Development for Asthma – Zacks.com

KaloBios to Stop KB003 Development for Asthma
Zacks.com
KaloBios Pharmaceuticals, Inc. (KBIO – Snapshot Report) announced disappointing top line results from a phase II study on KB003 in patients suffering from severe asthma, where the candidate failed to meet the key endpoints. We expect the news to have a 
KaloBios calls it quits on its asthma drug after a Phase II flopFierceBiotech
KaloBios Pharma pulls plug on asthma drug, shares plungeReuters
KaloBios Shares Slide on Move to Stop Asthma Treatment StudyWall Street Journal
RTT News –San Francisco Business Times (blog)
all 30 news articles »

View full post on asthma – Google News

KaloBios stock slides; to stop asthma study – MarketWatch

KaloBios stock slides; to stop asthma study
MarketWatch
KaloBios Pharmaceuticals Inc.'s (NASDAQ:KBIO) shares slumped after the company said it would discontinue development of a treatment for severe asthma, a move that followed disappointing Phase 2 results. Chief Executive Officer David Pritchard said 
KaloBios Reports Top-Line Data for Phase 2 Study of KB003 in Severe Asthma Benzinga

all 2 news articles »

View full post on asthma – Google News